← Back to Clinical Trials
Recruiting NCT06575881

Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Atrial Fibrillation
Sponsor Vanderbilt University Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-12-13
Completion 2028-12

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias. The investigators aim to study: 1. the prevalence and mechanism of inducible ventricular tachycardia 2. pace-mapping to define the site of origin of ventricular arrhythmias 3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy. Participants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 and older * Diagnosed with AF, frequent PVCs, or VT before age 60 * Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation * Able to provide written, informed consent * P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control. Exclusion Criteria: * Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure * VUS in 'possibly pathogenic' subgroup (control group only) * Previous PVC or VT ablation * LVEF \<20% * Prosthetic mitral or aortic valve * Contraindication to heparin * Prior myocardial infarction

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}